Fixed Income Research - The report highlights four key points regarding the EVE indicator for major banks, focusing on the impact of extended bond durations, deposit replacement, Tier 1 capital replenishment, and changes in the behavior of large banks in primary and secondary markets [2][3][4][5] - It emphasizes that the adjustment of the EVE indicator is more about risk mitigation rather than a significant increase in active long-term bond purchases by banks, suggesting that long-term supply pressures may limit the downward space for long-term interest rates [2][5] Metal New Materials Research: China Uranium Industry - China Uranium Industry derives over 90% of its revenue from natural uranium business and is the exclusive supplier of natural uranium products for its controlling shareholder, China National Nuclear Corporation (CNNC) [6][7] - The company is expected to see significant growth due to its role in national uranium supply and expansion in domestic capacity and overseas resource layout, with projected revenues of CNY 172.79 billion in 2024 and a net profit of CNY 14.58 billion [6][38] - The global uranium market is experiencing a supply-demand gap, with increasing demand driven by nuclear energy development, which is expected to benefit the company in the long term [8][40] Company Overview: China Uranium Industry - The company is the sole supplier of natural uranium products within CNNC, controlling 69.94% of the company’s shares, and has signed long-term supply agreements with China Nuclear Power [7][39] - It holds extensive domestic and international exploration and mining rights, with core uranium resources located in strategic areas such as Xinjiang and Namibia [7][39] - The report projects a net profit growth of CNY 17.62 billion, CNY 33.09 billion, and CNY 44.28 billion for the years 2025 to 2027, respectively, with corresponding EPS of CNY 0.85, CNY 1.60, and CNY 2.14 [6][38] Investment Recommendations - The report assigns a target price of CNY 80 for China Uranium Industry, based on a 50x PE valuation for 2026, and recommends an "Accumulate" rating [6][38] - The company is positioned to benefit from the long-term supply-demand gap in the uranium market, with a projected increase in global uranium demand expected to reach 150,500 tons by 2040 [8][40]

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [5]. Core Insights - The medical device industry in China has a prominent supply chain advantage, with overseas markets expected to maintain rapid growth. The brain-computer interface (BCI) sector is at a critical turning point, likely to see demand release. AI medical applications are gradually becoming operational, poised to reshape the health market [3]. Summary by Relevant Sections Investment Recommendations - For the overseas medical device sector, recommended stocks include: United Imaging Healthcare, Nanwei Medical, Microelectronic Physiology, Guichuang Tongqiao, Yuyue Medical, and New Industry. Stocks to watch include: Jingfeng Medical, MicroPort Scientific, and Chuangli Medical [5]. - In the brain-computer interface sector, recommended stocks are: Lepu Medical, Weisi Medical. Stocks to watch include: Meihao Medical, Xiangyu Medical, Mcland, Xinwei Medical, Aipeng Medical, Chengyitong, Chuangxin Medical, and Botuo Bio [5]. - For the AI + device sector, recommended stocks are: Yuyue Medical, BGI Genomics, KingMed Diagnostics, and United Imaging Healthcare. Stocks to watch include: Dian Diagnostics [5]. Overseas Market Growth - The supply chain advantage of domestic medical devices is significant, with exports expected to grow rapidly. In the first three quarters of 2025, United Imaging Healthcare's overseas revenue increased by 41.97% year-on-year, becoming a crucial growth driver for the company. The company continues to expand its market share in key regions due to superior product performance and localized service capabilities. By December 2025, MicroPort Scientific's global cumulative order volume exceeded 160 units, with core products in endoscopy, orthopedics, and vascular intervention surpassing 230 units in total orders. In 2025, Jingfeng Medical achieved a breakthrough in multiple key global markets, leading to explosive growth in overseas orders [5]. Brain-Computer Interface Market - The brain-computer interface market is at a pivotal turning point, with anticipated demand release. China's "14th Five-Year Plan" explicitly suggests a forward-looking layout for future industries, promoting BCI as a new economic growth point. In December 2025, Elon Musk announced that Neuralink would begin large-scale production of BCI devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process. In January 2026, China's BCI company Strong Brain Technology announced it had completed a new round of financing of approximately 2 billion yuan, setting a record for the second-largest single financing in the field globally, following Neuralink. The funds will be used to accelerate core technology research and development, extreme engineering breakthroughs, and product scaling and mass production [5]. AI Medical Applications - AI medical applications are gradually becoming operational, with the potential to reshape the health market. In June 2025, Ant Group launched the AI Health Manager AQ, which was officially upgraded to "Antifufu" in December 2025. By January 2026, the "Antifufu" app had over 30 million monthly active users, with daily inquiries exceeding 10 million, 55% of which came from third-tier cities and below. In January 2026, Tempus AI reported preliminary revenue of approximately 1.27 billion USD for 2025, representing an 83% year-on-year increase, exceeding initial expectations. OpenAI announced the acquisition of the healthcare tech startup Torch to expand into the healthcare sector, while Google launched the next-generation open-source medical AI model MedGemma1.5 and released the open-source medical speech-to-text model MedASR [5].

昨日A股呈现震荡分化格局，上证指数微跌0.31%，深证成指、创业板指分别上涨0.56%、0.82%，全市 场成交额达3.94万亿元续创历史新高，多空博弈激烈。板块层面，AI应用成为核心主线，AI营销、软件 开发、互联网电商涨幅均超4.5%，而电力设备、国防军工、银行板块领跌，资金呈现较为明显的切换 特征，主力资金连续7日净流出，单日净流出超700亿元，从高位电力设备、电子等板块撤离，而北向资 金逆势净流入，加仓计算机、通信、医药生物等赛道，AI医疗、创新药板块获北向资金净流入超50亿 元，全天融资余额明显减少，融资保证金比例上调至100%的政策效应显现，杠杆资金明显降温。 来源：中信建投证券 摘要：昨日A股呈现震荡分化格局，融资保证金比例上调至100%的政策效应显现，杠杆资金明显降 温。当前市场处于逆周期调节与产业支持并行，短期多空博弈加大，部分板块震荡回调后将迎来更好配 置机会，具体内容详见全文。 昨日市场冲高回落，沪指午后快速翻绿，此前一度涨超1%。沪深两市成交额3.94万亿，较上一个交易 日放量2904亿，连续第3个交易日突破3.5万亿。盘面上，市场热点快速轮动，全市场超2700只个股上 涨。从板块来看 ...

Core Viewpoint - The company has announced a significant stock price fluctuation, with a cumulative increase of over 30% in closing prices over three consecutive trading days, indicating abnormal trading activity [1] Group 1: AI Business Development - The company's AI application business in the financial sector has not yet generated revenue, indicating it is still in the early stages of market expansion [1] - The AI technology landscape is rapidly evolving, leading to intense market competition for the company's existing AI products, which may affect their contribution to overall performance [1] Group 2: Acquisition Announcement - The company has announced the acquisition of Cloud Edge Cloud Technology (Shanghai) Co., Ltd., which is currently in the delivery phase, and formal business cooperation has not yet commenced [1] - The integrated solution of "cloud network + AI + security" that is planned post-acquisition is still in the planning stages, with no significant impact on the company's performance at this time [1] Group 3: Business Stability - The company's main business has not undergone any changes, and the ongoing initiatives are still in the exploratory phase, with uncertainties surrounding the related technical solutions, application scenarios, and market benefits [1] - Investors are advised to approach the situation with rationality, as the current developments have not yet had a major impact on the company's financial performance [1]

Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative price increase exceeding 30% over three consecutive trading days from January 12 to 14, 2026, and confirmed no undisclosed significant matters as of the announcement date [1] Financial Performance - For the first three quarters of 2025, the company's revenue was 248.62 million, representing a year-on-year decline of 21.51% [1] - The net profit for the same period was -9.18 million, reflecting a year-on-year decrease of 124.88% [1] Business Development - The company's AI application business in the financial sector has not yet generated revenue [1] - The acquisition of Yunbian Cloud Technology is in the process of being finalized, with related business still in its early stages, leading to uncertain impacts on performance [1]

Group 1 - The core viewpoint of the article highlights the performance of Huatai Baoxing Health Consumption C and A funds, which experienced declines of 15.23% and 14.71% respectively in 2025 [1][2] - The top ten holdings of the funds are heavily concentrated in the biomedical sector, including companies such as Yuyue Medical, Mindray Medical, United Imaging, Aohua Endoscopy, Nanwei Medical, Anjiesi, Kaili Medical, Huitai Medical, Aibo Medical, and New Industry [1] - The fund manager, Zhao Xuzhao, has a background as a researcher at Guotai Junan Securities and has been with Huatai Baoxing Fund Management since December 2016, managing public funds for over seven years [1] Group 2 - The cumulative unit scale of Huatai Baoxing Health Consumption C is 0.04 billion, and for A it is 0.01 billion, both established on May 27, 2019 [2] - The net value growth rates for Huatai Baoxing Health Consumption C and A are -15.23% and -14.71% respectively, with their net values recorded at 0.9016 and 0.9441 [2]

Core Viewpoint - The domestic medical device market is transitioning to stable growth amid increasing pressure on medical insurance funds and comprehensive reforms in medical insurance payments, with "going global" becoming a strategic necessity for advanced domestic manufacturers [1] Group 1: Medical Equipment - High-end medical equipment has successfully moved beyond the stereotype of low-end replacements, with companies like United Imaging, Mindray, and MicroPort leading the charge into top-tier global medical systems with innovative products [2] - Establishing a global marketing network and supply chain is essential for the international business growth of medical devices, with companies like Yuyue Medical setting templates for localized operations through overseas subsidiaries [2] Group 2: High-Value Consumables - More domestic high-value consumables are obtaining FDA and EU certifications after initial experiences in Southeast Asia and South America, indicating growing international recognition of Chinese manufacturing [3] - Leading high-value consumables manufacturers are rapidly advancing their global strategies, with companies like Nanwei Medical acquiring major distributors and establishing factories in Thailand to mitigate policy risks [3] - Innovation is becoming a core competitive advantage for high-value consumables, with some products receiving breakthrough device designations from the FDA, showcasing significant clinical advancements [3] Group 3: Low-Value Consumables and IVD - The low-value consumables sector is undergoing a cleansing process, while the IVD sector is seeing steady growth in installed capacity, with expectations for increased reagent exports [4] - Companies like Mindray are exemplifying the IVD sector's international expansion through global marketing and supply chain integration, leading to sustained overseas performance [4]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 1.00% as of January 14, 2026, with Tianzhihang leading the gain at 18.97% and Rongchang Biopharmaceuticals experiencing the largest drop at 9.83% [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing the promotion of intelligent equipment iteration and supporting AI applications in high-end medical equipment and telemedicine [1] - Nvidia and Eli Lilly announced the establishment of an AI joint laboratory, planning to invest up to $1 billion over the next five years to accelerate drug development, indicating increased investment from leading overseas companies in domestic related fields [1] Group 2 - CITIC Securities reported that the medical AI sector is expected to accelerate the restructuring of the trillion-yuan pharmaceutical market, with a fundamental change in the payment logic for AI medical services anticipated in 2026 [2] - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 48.85% as of December 31, 2025, including companies like United Imaging Healthcare and BeiGene [2] Group 3 - The Jiashi Sci-Tech Medical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, providing an opportunity for investors to easily access the biopharmaceutical sector [3]

Group 1 - Semiconductor equipment stocks showed strong gains in early trading, driven by a recovery in domestic wafer fab capacity utilization and a strong willingness to expand production, indicating a "super cycle" phase in the global memory chip industry driven by AI [1] - The AI application sector is gaining strength again, with companies like Alibaba expected to release new generations of large models, indicating continuous catalysis in the AI industry and broad commercial development potential [1] - The STAR Market Index and its constituent stocks saw significant increases, likely driven by accelerated domestic semiconductor equipment production and multiple benefits from the AI industry chain [1] Group 2 - The STAR Market is clearly positioned to primarily serve innovative enterprises in key areas such as semiconductors, biomedicine, and high-end equipment, representing an investment in China's technological breakthroughs and domestic substitution frontiers [2] - In the context of changing external environments, technological self-sufficiency has become a top priority for national development, particularly in AI chips and semiconductor equipment, accelerating the domestic production process and providing significant growth opportunities for STAR Market companies [2] Group 3 - Related products include the STAR Market Index ETF Penghua (589680) and linked funds (Class A 023757, Class C 023758, Class I 024141) [3] - Related individual stocks include Cambricon-U (688256), Haiguang Information (688041), SMIC (688981), Zhongwei Company (688012), Kingsoft Office (688111), Lanke Technology (688008), Baile Tianheng (688506), United Imaging Healthcare (688271), Yingshi Innovation (688775), and Tuojing Technology (688072) [3]

Group 1: AI in Healthcare - Morgan Stanley's healthcare conference highlighted a partnership between Nvidia and Eli Lilly, investing $1 billion over five years to establish a joint research lab in the San Francisco Bay Area to accelerate AI drug development [1] - OpenAI launched ChatGPT Health, allowing users to securely connect medical records and health applications to an AI chatbot for health consultations and data interpretation [1] - Ant Group's AI health assistant "Ant Aifu" gained significant user attention by linking multiple hospitals and real doctors for health consultations and medical services [1] Group 2: Market Trends and Insights - CITIC Securities reported that by 2026, AI healthcare payment sources will become clearer and more robust, enhancing the commercial viability of AI in healthcare and accelerating the restructuring of the pharmaceutical market [2] - Aijian Securities noted rapid development in AI healthcare across policy, technology, products, and application scenarios, with future applications expected to extend from tertiary hospitals to grassroots terminals and individual users [2] - Guojin Securities emphasized that the Morgan Stanley healthcare summit serves as a global investment barometer, with several Chinese companies planning presentations that could boost expectations for innovative drug business development [2] Group 3: AI Medical Companies - Runta Medical launched a large model-based interpretation system for complex report analysis, assisting doctors in decision-making, and is developing automated pre-processing robots and logistics AGVs for sample handling [2] - Anbiping focuses on pathology diagnosis with digital pathology AI that can automatically identify cancerous areas and generate structured reports, while also developing automated slide scanning and staining robots [3] - United Imaging leverages AI in high-end medical imaging equipment, with an AI-assisted diagnostic system that can mark lesions in CT and MRI scans in real-time [3] Group 4: AI Drug Development - Hongbo Pharmaceutical has developed an AI drug design platform that supports new drug projects through CADD/AIDD technologies [4] - Chengdu XianDao is building a closed-loop R&D platform integrating a trillion-level small molecule compound library with AI and automation [4] - Hanyu Pharmaceutical collaborates with Huawei to develop a large model for peptide and oligonucleotide drug research, utilizing AI for molecular design and virtual screening [4] Group 5: CRO/CMO Services - WuXi AppTec operates as a fully integrated biopharmaceutical service platform, covering chemical drugs and cell gene therapies with global operational presence [5] - Zhaoyan New Drug focuses on preclinical CRO services, emphasizing safety evaluations and participating in clinical evaluations for stem cell and CAR-T cell therapies [5] - Tigermed provides full-process clinical trial services, with its subsidiary developing an AI model platform for new drug research and clinical trial support [6]